Displaying drugs 11176 - 11200 of 11518 in total
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … IMM-101 is a heat-inactivated immune-activating mycobacterial product. ... partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a …
Sugemalimab
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational
Matched Description: … Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals ... [L32868] Sugemalimab is under investigation in clinical trial NCT03802591 (A Study of CS1001 in Subjects …
Fobrepodacin
Investigational
9-(4-hydroxybutyl)-N2-phenylguanine
9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
Experimental
Matched Description: … 9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. …
TAK-428
TAK-428 is a drug for treating diabetic neuropathy. It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Investigational
Matched Description: … TAK-428 is a drug for treating diabetic neuropathy. …
Phenoxypropazine
Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the hydrazine chemical class. It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.
Withdrawn
Matched Description: … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging …
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
Matched Description: … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. …
GZ-389988
GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).
Investigational
Matched Description: … clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a …
Lixmabegagene relduparvovec
Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). It is under development for the treatment of GM1 gangliosidosis.
Experimental
Matched Description: … Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector …
Tosatoxumab
Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin.
Investigational
Matched Description: … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin …
Fidrisertib
Investigational
Fimepinostat
Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.
Investigational
PPI-1040
Investigational
Supinoxin
Supinoxin is under investigation in clinical trial NCT02003092 (RX-5902 Treatment of Subjects With Triple Negative Breast Cancer).
Investigational
R1626
R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication
Investigational
Matched Description: … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. …
Rilapladib
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
Investigational
Matched Description: … It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. …
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. …
Benactyzine
Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.
Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Withdrawn
Matched Description: … Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research …
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … EGT-301 is a gene therapy being investigated for Hunter Syndrome. …
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Matched Description: … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease …
HGTV-43
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Investigational
Matched Description: … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company …
(1R,2S)-2-Phenylcyclopropanaminium
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo …
VX-765
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase …
Displaying drugs 11176 - 11200 of 11518 in total